PMID- 30132286
OWN - NLM
STAT- MEDLINE
DCOM- 20190820
LR  - 20200225
IS  - 1720-8386 (Electronic)
IS  - 0391-4097 (Linking)
VI  - 42
IP  - 5
DP  - 2019 May
TI  - Impaired bone matrix glycoprotein pattern is associated with increased 
      cardio-metabolic risk profile in patients with type 2 diabetes mellitus.
PG  - 513-520
LID - 10.1007/s40618-018-0941-x [doi]
AB  - PURPOSE: Osteopontin (OPN), osteoprotegerin (OPG) and osteocalcin (OC) are matrix 
      glycoproteins which mediate bone mineralization; moreover, their effects on 
      glucose/insulin homeostasis have recently been demonstrated. Higher circulating 
      OPN and OPG levels have been associated with the presence of insulin resistance, 
      atherosclerosis and coronary heart disease. No data are available on contextual 
      changes of these markers in type 2 diabetes mellitus (T2DM). Therefore, aims of 
      this study were to evaluate serum OPN, OPG and OC levels in T2DM patients and 
      their clinical correlates. METHODS: We recruited 83 consecutive T2DM patients 
      referring to our diabetes outpatient clinics at Sapienza, University of Rome, and 
      71 non-diabetic sex and age-comparable subjects as a control group. Study 
      population underwent metabolic characterization and carotid ultrasound for 
      intima-media thickness measurement. Plasma OPN, OPG and OC were measured by 
      MILLIPLEX Multiplex Assays Luminex. RESULTS: T2DM patients had significantly 
      higher circulating OPN and OPG levels than controls (14.3 +/- 13.6 vs 
      10.6 +/- 13.7 ng/ml p < 0.001, 0.70 +/- 0.60 vs 0.54 +/- 4.1 ng/ml, p = 0.02) while OC 
      levels were similar in the two cohorts (6.35 +/- 5.8 vs 7.80 +/- 7.0 ng/ml, p = n.s). 
      OPN and OPG positively correlated with greater systolic blood pressure (SBP) 
      values, HOMA-IR and HOMA-beta, and with the presence of dyslipidemia and carotid 
      atherosclerosis. The association between greater OPN and OPG levels and SBP was 
      independent from possible confounders (both p = 0.01). CONCLUSIONS: Circulating 
      OPN and OPG levels are increased in T2DM patients and identify a particularly 
      unfavourable metabolic profile, mostly expressed by higher SBP. Bone peptides may 
      represent novel markers of vascular stress and accelerated atherosclerosis in 
      diabetes, constituting a possible tool for cardiovascular risk stratification in 
      diabetes.
FAU - Barchetta, I
AU  - Barchetta I
AD  - Department of Experimental Medicine, Section of Medical Pathophysiology, Food 
      Science and Endocrinology, Sapienza University of Rome, Rome, Italy.
FAU - Ceccarelli, V
AU  - Ceccarelli V
AD  - Department of Experimental Medicine, Section of Medical Pathophysiology, Food 
      Science and Endocrinology, Sapienza University of Rome, Rome, Italy.
FAU - Cimini, F A
AU  - Cimini FA
AD  - Department of Experimental Medicine, Section of Medical Pathophysiology, Food 
      Science and Endocrinology, Sapienza University of Rome, Rome, Italy.
FAU - Bertoccini, L
AU  - Bertoccini L
AD  - Department of Experimental Medicine, Section of Medical Pathophysiology, Food 
      Science and Endocrinology, Sapienza University of Rome, Rome, Italy.
FAU - Fraioli, A
AU  - Fraioli A
AD  - Department of Internal Medicine and Medical Specialties, Sapienza University of 
      Rome, Rome, Italy.
FAU - Alessandri, C
AU  - Alessandri C
AD  - Department of Internal Medicine and Medical Specialties, Sapienza University of 
      Rome, Rome, Italy.
FAU - Lenzi, A
AU  - Lenzi A
AD  - Department of Experimental Medicine, Section of Medical Pathophysiology, Food 
      Science and Endocrinology, Sapienza University of Rome, Rome, Italy.
FAU - Baroni, M G
AU  - Baroni MG
AD  - Department of Experimental Medicine, Section of Medical Pathophysiology, Food 
      Science and Endocrinology, Sapienza University of Rome, Rome, Italy.
FAU - Cavallo, M G
AU  - Cavallo MG
AD  - Department of Experimental Medicine, Section of Medical Pathophysiology, Food 
      Science and Endocrinology, Sapienza University of Rome, Rome, Italy. 
      gisella.cavallo@uniroma1.it.
LA  - eng
PT  - Journal Article
DEP - 20180821
PL  - Italy
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
RN  - 0 (BGLAP protein, human)
RN  - 0 (Biomarkers)
RN  - 0 (Osteoprotegerin)
RN  - 0 (SPP1 protein, human)
RN  - 0 (TNFRSF11B protein, human)
RN  - 104982-03-8 (Osteocalcin)
RN  - 106441-73-0 (Osteopontin)
MH  - Adult
MH  - Aged
MH  - Biomarkers/*blood
MH  - Cardiovascular Diseases/*blood/diagnosis/etiology
MH  - Case-Control Studies
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/blood/*complications
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Metabolic Syndrome/*blood/diagnosis/etiology
MH  - Metabolome
MH  - Middle Aged
MH  - Osteocalcin/blood
MH  - Osteopontin/*blood
MH  - Osteoprotegerin/*blood
MH  - Prognosis
MH  - Risk Factors
OTO - NOTNLM
OT  - Glycoproteins
OT  - Osteocalcin
OT  - Osteopontin
OT  - Osteoprotegerin
OT  - Type 2 diabetes
EDAT- 2018/08/23 06:00
MHDA- 2019/08/21 06:00
CRDT- 2018/08/23 06:00
PHST- 2018/05/11 00:00 [received]
PHST- 2018/08/09 00:00 [accepted]
PHST- 2018/08/23 06:00 [pubmed]
PHST- 2019/08/21 06:00 [medline]
PHST- 2018/08/23 06:00 [entrez]
AID - 10.1007/s40618-018-0941-x [pii]
AID - 10.1007/s40618-018-0941-x [doi]
PST - ppublish
SO  - J Endocrinol Invest. 2019 May;42(5):513-520. doi: 10.1007/s40618-018-0941-x. Epub 
      2018 Aug 21.